Supernus Pharmaceuticals (NASDAQ:SUPN) Given New $55.00 Price Target at Stifel Nicolaus

Supernus Pharmaceuticals (NASDAQ:SUPN) had its price target increased by equities researchers at Stifel Nicolaus from $50.00 to $55.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “hold” rating on the specialty pharmaceutical company’s stock. Stifel Nicolaus’ price objective would suggest a potential upside of 9.01% from the company’s previous close.

A number of other research analysts have also commented on the company. Bank of America began coverage on Supernus Pharmaceuticals in a research report on Wednesday, October 29th. They set a “buy” rating and a $65.00 price target for the company. TD Cowen raised their price target on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Wall Street Zen raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Zacks Research lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, December 8th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Supernus Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $61.60.

Supernus Pharmaceuticals Price Performance

Supernus Pharmaceuticals stock traded up $1.18 during trading hours on Friday, reaching $50.46. The company had a trading volume of 81,284 shares, compared to its average volume of 690,105. Supernus Pharmaceuticals has a 12-month low of $29.16 and a 12-month high of $57.65. The company has a 50-day moving average price of $48.22 and a 200 day moving average price of $42.24. The firm has a market cap of $2.89 billion, a price-to-earnings ratio of -148.42, a P/E/G ratio of 0.59 and a beta of 0.71.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). The company had revenue of $170.00 million for the quarter, compared to analysts’ expectations of $175.82 million. Supernus Pharmaceuticals had a negative net margin of 2.81% and a positive return on equity of 11.51%. The business’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same period last year, the company posted $0.69 EPS. As a group, research analysts expect that Supernus Pharmaceuticals will post 2.38 earnings per share for the current year.

Insider Activity at Supernus Pharmaceuticals

In other news, CEO Jack A. Khattar sold 59,900 shares of the firm’s stock in a transaction on Thursday, October 9th. The stock was sold at an average price of $50.57, for a total value of $3,029,143.00. Following the transaction, the chief executive officer directly owned 1,206,578 shares in the company, valued at $61,016,649.46. This trade represents a 4.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have sold 116,235 shares of company stock valued at $5,694,447 in the last three months. Insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SUPN. Tudor Investment Corp ET AL purchased a new stake in Supernus Pharmaceuticals in the 3rd quarter worth $1,434,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Supernus Pharmaceuticals during the third quarter worth about $275,000. Jacobs Levy Equity Management Inc. purchased a new stake in Supernus Pharmaceuticals during the 3rd quarter valued at approximately $1,872,000. Caxton Associates LLP bought a new stake in shares of Supernus Pharmaceuticals during the third quarter valued at approximately $1,117,000. Finally, Woodline Partners LP lifted its holdings in shares of Supernus Pharmaceuticals by 63.5% in the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock worth $60,398,000 after buying an additional 490,835 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.